Zoe Braybrook

Technology Networks had the pleasure of talking to Wilfredo Marín to learn more about OPC UA and how it is suited to biobanking and cell and gene therapy development.

While oncolytic virus (OV) therapy has garnered increasing attention from the cancer research community, this therapeutic strategy doesn’t come without its challenges, as a patient’s immune system can sometimes mount a response to the OVs before they reach their intended target. To address this, Calidi Biotherapeutics has developed cell-based platforms to shield OVs from the immune system, so that they can effectively target and destroy the cancer cells.

Technology Networks had the pleasure of speaking with Thermo Fisher Scientific’s Don Paul Kovarcik, to learn more about the benefits and limitations of electroporation and key factors affecting electroporation performance.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.

Technology Networks spoke to Stefan Baier, head of food science at Motif FoodWorks, to learn more about the exclusive access to transformative plant-based food technologies the company has recently been granted. He also highlights the role plant-based foods play in protecting the environment and the importance of flavor and texture when developing plant-based foods.